

## Kevin C. Clayton

Partner

Washington, D.C.

### Biography

Kevin Clayton is a practical and experienced adviser who brings a collaborative and cost-effective approach to corporate and commercial matters. He regularly advises clients on mergers and acquisitions, equity and debt financings, joint ventures and complex contracting and corporate governance matters, particularly focusing on representation of funds, corporate investors, and emerging companies from start-up through unicorn in financing, commercial, and acquisition transactions.

Legal500 commends Kevin noting that he is 'responsive; gives thoughtful advice, is very knowledgeable and has a good sense of the market'. In addition to his two decades of advising on mergers and acquisitions and financing transactions, Kevin also has years of experience managing a wide array of commercial matters and complex contracting arrangements, such as joint venture, license, supply, distribution, collaboration, manufacturing, service, employment, and consulting agreements.

While Kevin often represents emerging and growth-stage companies on formation, financing, commercial, and acquisition matters, he also advises later-stage and public companies, particularly with respect to investment, acquisition, joint venture and licensing transactions.

Kevin represents clients in various industry sectors, but has particular experience with matters in the life sciences and technology sectors.



### Phone

+1 202 637 5489

### Fax

+1 202 637 5910

### Email

[kevin.clayton@hoganlovells.com](mailto:kevin.clayton@hoganlovells.com)

---

### Practices

Venture Capital and Emerging Companies

Mergers and Acquisitions

Private Equity

Joint Ventures

Commercial

Complex Contracting

IP and Technology Transactions

Trade Secrets and Confidential Know-how

Privacy and Cybersecurity

Investment Funds

Space and Satellite

Uncrewed Aircraft Systems

---

Additionally, Kevin is currently a lecturer on corporate transactions at the University of Virginia School of Law.

## Representative experience

Advising Ford Motor Company on Volkswagen AG's US\$2.6bn investment into Ford's autonomous vehicle platform company, Argo AI, and certain venture investments.

Represented Gilead Sciences and Kite Pharma in multiple venture investments.

Represented a publicly traded biotechnology company in several acquisitions and divestitures and numerous strategic venture investments.

Represented Daimler AG in its investment in Via Transportation, Inc.

Represented RTW Investments on venture investments in Monte Rosa Therapeutics' US\$95m Series C financing, Acelyrin's US\$250m Series B financing and InBrace's US\$102m Series D financing.

Represented Paladin Capital on multiple venture investments.

Represented OptiNose, Inc. in its US\$37m Series D financing, prior equity and debt financings, and general corporate matters.

Represented Fred Hutchinson Cancer Research Center in Juno Therapeutics, Inc.'s formation and US\$176m Series A financing, US\$134m Series B financing, and related matters.

Represented New Enterprise Associates in multiple venture capital investments.

Represented PhishMe, Inc. in its US\$42m Series C financing, prior equity and debt financings, general corporate matters, and its transaction with Malcovery Security, LLC.

Represented Avidea Technologies in its acquisition by Vaccitech PLC.

## Industries

Private Capital

Life Sciences and Health Care

Automotive and Mobility

Technology and Telecoms

Education

Aerospace and Defense

---

## Areas of focus

Emerging Companies

Private Equity and Venture Capital Funds

Company Formation

Exits

Carve-outs, Spin-offs, and Split-offs

Cross-border Mergers and Acquisitions

Corporate Group Structures

IP Rights in Transactions

Technology Contracts

Licensing and Commercial Transactions

Agency and Distribution

Manufacturing

Corporate and Commercial Transactions

Emerging Companies and Investors - Life Sciences and Health Care

Automotive Venture Capital Investors

Consumer Venture Capital Investors

FinTech

Financial Venture Capital Investors

Represented Dental Care Alliance, LLC in its 2015 sale to Harvest Partners, LP.

Represented New York University in connection with Spin Transfer Technologies, Inc.'s US\$70m financing and other similar transactions.

Represented a luxury vacation club in a variety of equity financings, mortgage-backed debt financings, and acquisitions.

Represented American Institutes for Research in the sale of its Assessment Division to Cambium Learning.

Represented American Institutes for Research in its acquisition of Impaq, LLC.

Represented Applied Materials Ventures in multiple venture investments.

Represented Orbit Fab, Inc. in several financing rounds.

Represented RangeForce, Inc. in several financing rounds.

## Awards and rankings

- M&A/Corporate and Commercial, Venture Capital and Emerging Companies, *Legal500 US*, 2022

## Latest thinking and events

- News
  - Silicon Valley Bank (SVB) and Signature Bank Collapses: Your legal and regulatory FAQs answered
- Press releases
  - Hogan Lovells advises Avidea Technologies on acquisition by Vaccitech

FinTech Venture Capital

Life Sciences and Health Care  
Venture Capital Investors

Strategic / Corporate Venture  
Capital Investors

Technology Venture Capital  
Investors

Raising Equity Capital

Connected Cars

Cell, Tissue, and Gene Therapies

Hospitals and Health Care Providers

Medical Devices

Pharmaceuticals and Biotechnology

Hotels and Leisure

---

## Education and admissions

### Education

J.D., University of Virginia School of Law, 1998

B.A., University of Virginia, 1992

---

### Bar admissions and qualifications

District of Columbia

Virginia

---

### Accolades

Kevin Clayton excels at quickly digesting complex issues and explaining them in ways which are accessible and focused on how to get to sensible business outcomes – all while being calm, responsive, and just a pleasure to work with.

Kevin Clayton is responsive, gives thoughtful advice, is very knowledgeable and has a good sense of the market.